Koninklijke DSM (RDSMY) Upgraded to “Buy” by Deutsche Bank
A number of other equities analysts have also issued reports on RDSMY. Zacks Investment Research lowered Koninklijke DSM from a buy rating to a hold rating in a research report on Tuesday, September 19th. assumed coverage on Koninklijke DSM in a research report on Friday, September 1st. They issued a buy rating on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus target price of $24.00.
Shares of Koninklijke DSM (RDSMY) traded up $0.06 on Friday, hitting $23.47. The company’s stock had a trading volume of 84,746 shares, compared to its average volume of 38,687. Koninklijke DSM has a one year low of $14.50 and a one year high of $23.50. The firm has a market cap of $16,980.00, a price-to-earnings ratio of 29.26, a price-to-earnings-growth ratio of 2.89 and a beta of 1.28. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.11 and a current ratio of 1.74.
Koninklijke DSM Company Profile
Koninklijke DSM N.V. (Royal DSM) is a global science-based company, engaged in offering health, nutrition and materials. The Company’s segments include Nutrition, Performance Materials, Innovation Center and Corporate Activities. Its Nutrition segment includes DSM Nutritional Products and DSM Food Specialties.
Receive News & Ratings for Koninklijke DSM NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM NV and related companies with Analyst Ratings Network's FREE daily email newsletter.